RFP
ADCT icon

Root Financial Partners’s ADC Therapeutics ADCT Stock Holding History

Root Financial Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89
Closed -$334 – 447
2026
Q1 		$334 Buy
+89
New +$351 ﹤0.01% 2995

Other funds holding ADCT

SCTC
Sanibel Captiva Trust Company Sanibel, Florida $4.02B AUM 34.36% 1-Year Est. Return
RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
SCM
Saxony Capital Management St. Louis, Missouri $218M AUM 24.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Root Financial Partners's ADCT Position: Q2 2026 in Review

Root Financial Partners sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 89 shares — an estimated $334 sold.

Root Financial Partners first reported a position in ADCT in Q1 2026 and held it in 1 quarter. The position peaked at $334 in Q1 2026. 17 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Root Financial Partners reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 89 ADC Therapeutics shares in Q2 2026, an estimated $334.
  • Root Financial Partners first reported a position in ADC Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's ADC Therapeutics position peaked at $334 in Q1 2026.
  • 17 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.